Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) Short Interest Update

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) was the target of a significant decrease in short interest in December. As of December 15th, there was short interest totalling 59,600 shares, a decrease of 50.7% from the November 30th total of 120,900 shares. Approximately 0.2% of the shares of the stock are sold short. Based on an average daily trading volume, of 149,700 shares, the days-to-cover ratio is presently 0.4 days.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Bolt Biotherapeutics stock. Acuitas Investments LLC lifted its stake in shares of Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) by 21.7% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 630,507 shares of the company’s stock after purchasing an additional 112,555 shares during the quarter. Acuitas Investments LLC owned 1.65% of Bolt Biotherapeutics worth $473,000 as of its most recent filing with the Securities and Exchange Commission. 86.70% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Separately, HC Wainwright reiterated a “neutral” rating on shares of Bolt Biotherapeutics in a research report on Wednesday, November 13th. Five equities research analysts have rated the stock with a hold rating, According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $3.50.

Bolt Biotherapeutics Price Performance

Shares of NASDAQ BOLT traded up $0.01 during trading hours on Friday, hitting $0.52. 257,086 shares of the stock were exchanged, compared to its average volume of 167,273. Bolt Biotherapeutics has a 1-year low of $0.48 and a 1-year high of $1.56. The company has a market cap of $19.83 million, a PE ratio of -0.30 and a beta of 0.93. The company has a debt-to-equity ratio of 0.21, a quick ratio of 3.16 and a current ratio of 3.16. The company’s fifty day simple moving average is $0.59 and its two-hundred day simple moving average is $0.66.

Bolt Biotherapeutics (NASDAQ:BOLT) last issued its earnings results on Tuesday, November 12th. The company reported ($0.40) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.04). Bolt Biotherapeutics had a negative net margin of 665.56% and a negative return on equity of 69.46%. The business had revenue of $1.14 million during the quarter, compared to analyst estimates of $1.02 million. On average, sell-side analysts predict that Bolt Biotherapeutics will post -1.61 EPS for the current year.

About Bolt Biotherapeutics

Bolt Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company’s lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer.